

**MATERIAL CHANGE
REPORT FORM 51-102F3**

1. **Reporting Issuer**

Canntab Therapeutics Limited (the “**Issuer**” or “**Canntab**”)
223 Riviera Drive
Markham, Ontario, L3R 5J6

2. **Date of Material Change**

November 16, 2020.

3. **News Release**

A news release with respect to the material change referred to in this report was disseminated on November 16, 2020 through Newsfile and filed on the system for electronic document analysis and retrieval (SEDAR) at www.sedar.com.

4. **Summary of Material Change**

The Issuer has announced that Canntab and Exactus, Inc. have mutually agreed to terminate the supply and distribution agreements previously announced on November 20, 2019, after determining that the regulatory requirements could not be completed on a timely basis.

5. **Full Description of Material Change**

The material change is fully described in the news release attached hereto as Schedule "A".

6. **Reliance on Section 7.1(2) of National Instrument 51-102**

Not applicable.

7. **Omitted Information**

Not applicable.

8. **Executive Officer**

For additional information with respect to this material change, the following person may be contacted:

Canntab Therapeutics Limited
Jeffrey Renwick, CEO
Tel: +1 289.301.3812
Email: jeff@canntab.ca

9. **Date of Report**

This report is dated as of the 16th day of November, 2020.

Schedule "A"

CANNTAB THERAPEUTICS ANNOUNCES END OF SUPPLY AND DISTRIBUTION AGREEMENTS WITH EXACTUS

TORONTO, November 16, 2020 /Newsfile/ - Canntab Therapeutics Limited (CSE: PILL.CN) (OTCQB: CTABF) (FRA: TBF1.F) (the "**Company**" or "**Canntab**"), the leading innovator in cannabinoid and terpene blends in hard pill form for therapeutic applications, announces that Canntab and Exactus, Inc. have mutually agreed to terminate the supply and distribution agreements previously announced on November 20, 2019, after determining that the regulatory requirements could not be completed on a timely basis.

During a time of pandemic and closed borders, both companies decided it would be best to mutually terminate the agreements in place. However, both companies have expressed an interest in working together in the future, and intend to make a decision in that regard once circumstances surrounding the COVID-19 pandemic have improved.

About Canntab Therapeutics

Canntab Therapeutics is a Canadian biopharmaceutical company focused on the manufacturing and distribution of a suite of hard pill cannabinoid formulations in multiple doses and timed-release combinations. Long referred to as Cannabis 3.0 by the Company, Canntab's proprietary hard pill cannabinoid formulations provide doctors, patients and consumers with medical grade solutions which incorporate all the features one would expect from any prescription or over the counter medication sold in pharmacies around the world. These will include the following formulations: once a day and extended release, both providing an accurate dose and improved shelf stability. Canntab holds a Cannabis Standard Processing & Sales for Medical Purposes License, a Cannabis Research License, and an Industrial Hemp License from Health Canada. Canntab trades on the Canadian Securities Exchange under the symbol PILL, on the OTCQB under the symbol CTABF, and on the Frankfurt Stock Exchange under the symbol TBF1.

For more information, please contact:

Canntab Therapeutics Limited:

Larry Latowsky, Chief Executive Officer, T: +1 833 301-3812, E: larry@canntab.ca; Richard Goldstein, Chief Financial Officer, T: +1 833 301-3812, E: richard@canntab.ca; Frank Candido, Business Development and Investor Relations, T: 514-969- 5530, E: Frank@canntab.ca